YiChang HEC ChangJiang Pharmaceutical Co., Ltd. board of directors announced that, based on the currently available unaudited management accounts of the Group and the preliminary assessment by the company's management, it is expected that the Group will record an increase in profit attributable to equity shareholders of the Company of no less than 120% for the year ended 31 December 2019 (without considering the impact of convertible bonds), as compared to year ended 31 December 2018. The expected increase in profit attributable to equity shareholders of the Company is primarily attributed to: (i) the continuous increase in the sales revenue of Kewei, the Company's core product; (ii) the increasing penetration of the Company's products in medical institutions across the country; and (iii) the continuous promotion efforts by the Company on its products in professional academic circles.